Grieve A P
Biometrics Department, Pfizer Central Research, Sandwich, Kent, U.K.
Stat Med. 1998;17(15-16):1715-23; discussion 1741-3. doi: 10.1002/(sici)1097-0258(19980815/30)17:15/16<1715::aid-sim973>3.0.co;2-6.
Economic evaluations of new pharmaceutical products are of increasing importance to pharmaceutical companies. In this paper we investigate a number of topics of greater or lesser importance to statisticians who need to involve themselves in pharmaco-economic evaluations. These range from the need to consider whether traditional randomized clinical trials provide the most appropriate setting for an economic evaluation, to the more technical question of how to handle cost-effectiveness ratio data, including the issue of the most appropriate inferential apparatus-hypothesis testing, confidence intervals or Bayesian methods.
对制药公司而言，新药品的经济评估愈发重要。在本文中，我们探讨了一些对需要参与药物经济学评估的统计学家或多或少具有重要性的主题。这些主题涵盖了从是否需要考虑传统随机临床试验是否为经济评估提供最合适的环境，到如何处理成本效益比数据这一更为技术性的问题，包括最合适的推断方法——假设检验、置信区间或贝叶斯方法的问题。
